Education
About Us
Working with TipRanks
Follow Us
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
RESEARCH TOOLSreports
GDTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.20 - $4.05
Previous CloseN/A
Volume107.31K
Average Volume (3M)14.09K
Market Cap
$25.16M
Enterprise Value$19.54M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
May 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding11,540,000
10 Day Avg. Volume16,889
30 Day Avg. Volume14,086
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)78.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit91.71
Enterprise Value/Ebitda-4.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
CytoMed Therapeutics Limited News
PremiumCompany Announcements
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India
PremiumCompany Announcements
CytoMed Therapeutics Expands Leadership Amid Strategic Growth
PremiumCompany Announcements
CytoMed Reaches Milestone with New Cancer Therapy
PremiumCompany Announcements
CytoMed Launches Innovative CAR-T Cell Trial---
Ownership Overview
39.34% Insiders
0.04%
Mutual Funds
0.05% Other Institutional Investors
60.57% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $1.20 and its highest was $4.05 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $25.16M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
CytoMed Therapeutics Limited’s upcoming earnings report date is May 05, 2025 which is in 32 days.
How were CytoMed Therapeutics Limited’s earnings last quarter?
CytoMed Therapeutics Limited released its earnings results on Oct 08, 2024. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.01.
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,540,000 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
CytoMed Therapeutics Limited reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
---
CytoMed Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $229.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.78%
12-Months-Change
Fundamentals
Return on Equity
-26.36%
Trailing 12-Months
Asset Growth
-21.71%
Trailing 12-Months
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
---
GDTC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Nektar Therapeutics
―
Fate Therapeutics
―
CryoPort
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
---